Pharma News
Sandoz makes biological deal in China
Sandoz has made a deal for copy biological in China in December 2018, and received approval of an extra indication for its biosimilar etanercept in January 2019.
AbbVie makes more deals delaying adalimumab biosimilars in the US
Last update: 14 December 2018
US-based pharma giant AbbVie has signed yet more deals with biosimilars makers regarding biosimilar versions of its blockbuster arthritis drug Humira (adalimumab).
Samsung Bioepis makes deals for copy biologicals in China
Samsung Bioepis has made deals with two Chinese firms to expand its business in the country.
Fuji Pharma acquires stake in Alvotech
Iceland-based biopharmaceutical company Alvotech announced on 19 November 2018 that Japan-based Fuji Pharma was investing in the company.
Glenmark makes deal for ophthalmic generics
Indian generics maker Glenmark Pharmaceuticals (Glenmark) has entered into an exclusive agreement with South Korea’s Sam Chun Dang Pharm (SCD) to develop, manufacture and market a portfolio of generic ophthalmic products in the US and Canada.
Top 10 most read GaBI Online articles in 2018
A review of the important events for biosimilars during 2018 are presented in this article. Some of the most memorable events for biosimilars in 2018 were the rejections by the US Food and Drug Administration (FDA) of four biosimilars and the agency’s update on its naming guideline for biologicals. Other subjects of interest for biosimilars were European Medicines Agency approvals, the US biosimilars market, biosimilar policies in Europe, position statements on biosimilars and interchangeability and switching.
Samsung BioLogics sues Korea’s FSC over accounting discrepancies
Samsung BioLogics is fighting back against allegations of accounting fraud and has launched a lawsuit against the South Korean financial authority, the Financial Services Commission (FSC).
Health care in Iraq saves money by incorporating off-patent biologicals
Iraq is one of many countries determined to increase its budget savings by replacing appropriate originator biologicals with off-patent biologicals. This is due to the recognition of the proven impact off-patent biologicals have on the financial burden of healthcare systems worldwide [1, 2].
Alvotech makes deal with Fuji Pharma for biosimilars in Japan
Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 19 November 2018 that they had entered into an exclusive partnership for biosimilars in Japan.
Amgen collaborates with Orion to market Amgevita in Finland
The Orion Group announced on 24 October 2018 that it will distribute Amgen’s adalimumab biosimilar in Finland.
